<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262314</url>
  </required_header>
  <id_info>
    <org_study_id>24293</org_study_id>
    <secondary_id>19-297</secondary_id>
    <nct_id>NCT00262314</nct_id>
    <nct_alias>NCT00016614</nct_alias>
  </id_info>
  <brief_title>Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients</brief_title>
  <acronym>RENEW</acronym>
  <official_title>Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <brief_summary>
    <textblock>
      The overall objective of this study is to collect data relevant to the tolerability of
      Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring
      recommendations specified in the package insert.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase IV, multicenter, prospective, open-label tolerability and safety monitoring study
      will enroll a select cohort of 500 multiple sclerosis patients receiving commercially
      available Novantrone®. The patients will be assessed every 3 months during treatment followed
      by annual assessment for a total of five (5) years.

      The select cohort of MS patients enrolled will have secondary (chronic) progressive,
      progressive relapsing, or worsening relapsing-remitting disease (i.e., patients whose
      neurological status is significantly abnormal between relapses).

      The overall objective of this study is to collect data relevant to the tolerability of
      Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring
      recommendations specified in the package insert.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Congestive Heart Failure (Treatment Phase)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Number of patients experiencing congestive heart failure during the treatment phase of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Congestive Heart Failure (Annual Follow-Up Phase)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Number of patients experiencing congestive heart failure during the annual follow-up phase of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction (Treatment Phase)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Number of patients with left ventricular ejection fraction test results that decreased below 50% during the treatment phase of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction (Annual Follow-Up Phase)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Number of patients with left ventricular ejection fraction test results that decreased below 50% during the annual follow-up phase of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Infections (Treatment Phase)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Number of serious infections during the treatment phase of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Infections (Annual Follow-Up Phase)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Number of serious infections during the annual follow-up phase of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IV Antibiotics (Individual Drugs Unspecified) Utilized Due to Serious Infection (Treatment Phase)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Number of subjects in whom IV antibiotics were utilized due to serious infection during the treatment phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IV Antibiotics (Individual Drugs Unspecified) Utilized Due To Serious Infection (Annual Follow-Up Phase)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Number of subjects in whom IV antibiotics were utilized due to serious infection during the annual follow-up phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe Neutropenia (Treatment Phase)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Number of infections associated with severe neutropenia at onset during the treatment phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe Neutropenia (Annual Follow-Up Phase)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Number of infections associated with severe neutropenia at onset during the annual follow-up phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Relapses (Treatment Phase)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Number of clinical relapses reported during the treatment phase of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Relapses (Annual Follow-Up Phase)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Number of clinical relapses reported during the annual follow-up phase of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatic CHF, Left Ventricular Ejection Fraction - Prior to Each Dose • Serious Infections, IV Antibiotics, or Assoc w/ Severe Neutropenia-evaluated. Novantrone Admin - Per PI • SAE, Clinical Relapses</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Outcomes are presented separately above apart from adverse events which are presented in the adverse event section</description>
  </primary_outcome>
  <enrollment type="Actual">509</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients with a clinically definite or laboratory supported diagnosis of MS
        and having secondary (chronic) progressive, progressive relapsing, or worsening
        relapsing-remitting disease (i.e., patients whose neurologic status is significantly
        abnormal between relapses). Patients with primary progressive disease will not be included
        in this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be eligible for inclusion into this study, the subjects must fulfill all of the
             following criteria:

          -  Platelet count &gt;100,000 cells/µL

          -  Granulocyte count &gt; 2000 cells/µL

          -  Age 18-65 years

          -  Negative pregnancy test for female patients who are biologically capable of becoming
             pregnant, even if they are taking birth control

          -  For patients of reproductive age, agreement to practice effective contraception
             throughout the study and for 6 months following the last administration of Novantrone®

          -  Signed Inform Consent.

        Exclusion Criteria:

          -  To be eligible for inclusion in this study the subjects must not meet any of the
             following criteria:

          -  Presence of cardiac risk factors:

          -  History of congestive heart failure

          -  LVEF &lt; 50% determined by echocardiography or MUGA

          -  Previous treatment with Novantrone®, other anthracenediones, or anthracyclines

          -  Prior mediastinal radiotherapy or total lymphoidal irradiation

          -  AST, ALT, bilirubin &gt; 2x upper limits of normal

          -  Severe untreated infection (including current urinary tract infection)

          -  Nursing or pregnant women)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randy Bennett</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Registrat Inc</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504-3276</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <results_first_submitted>May 21, 2010</results_first_submitted>
  <results_first_submitted_qc>May 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2010</results_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitoxantrone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Trial Initiation Date: 17 October 2000 (date of first subject first visit). Trial Completion Date 15 July 2008 (date of last subject last visit). 46 centers enrolled at least one subject.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Novantrone Therapy</title>
          <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="509">Patients with validated data who received at least 1 dose of Novantrone®</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172">Patients in the study for 5 years +/-3 months are considered to have completed the 5-year study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="337"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Changing physicians</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient's decision</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Novantrone Therapy</title>
          <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="509"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="19" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Congestive Heart Failure (Treatment Phase)</title>
        <description>Number of patients experiencing congestive heart failure during the treatment phase of the trial</description>
        <time_frame>up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Congestive Heart Failure (Treatment Phase)</title>
          <description>Number of patients experiencing congestive heart failure during the treatment phase of the trial</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Congestive Heart Failure (Annual Follow-Up Phase)</title>
        <description>Number of patients experiencing congestive heart failure during the annual follow-up phase of the trial</description>
        <time_frame>up to 5 years</time_frame>
        <population>participants with annual follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Congestive Heart Failure (Annual Follow-Up Phase)</title>
          <description>Number of patients experiencing congestive heart failure during the annual follow-up phase of the trial</description>
          <population>participants with annual follow up data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Ejection Fraction (Treatment Phase)</title>
        <description>Number of patients with left ventricular ejection fraction test results that decreased below 50% during the treatment phase of the trial</description>
        <time_frame>up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (Treatment Phase)</title>
          <description>Number of patients with left ventricular ejection fraction test results that decreased below 50% during the treatment phase of the trial</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Ejection Fraction (Annual Follow-Up Phase)</title>
        <description>Number of patients with left ventricular ejection fraction test results that decreased below 50% during the annual follow-up phase of the trial</description>
        <time_frame>up to 5 years</time_frame>
        <population>participants with annual follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (Annual Follow-Up Phase)</title>
          <description>Number of patients with left ventricular ejection fraction test results that decreased below 50% during the annual follow-up phase of the trial</description>
          <population>participants with annual follow up data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Infections (Treatment Phase)</title>
        <description>Number of serious infections during the treatment phase of the trial</description>
        <time_frame>up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Infections (Treatment Phase)</title>
          <description>Number of serious infections during the treatment phase of the trial</description>
          <units>number of infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serious Infections (Annual Follow-Up Phase)</title>
        <description>Number of serious infections during the annual follow-up phase of the trial</description>
        <time_frame>up to 5 years</time_frame>
        <population>participants with annual follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Infections (Annual Follow-Up Phase)</title>
          <description>Number of serious infections during the annual follow-up phase of the trial</description>
          <population>participants with annual follow up data</population>
          <units>number of infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IV Antibiotics (Individual Drugs Unspecified) Utilized Due to Serious Infection (Treatment Phase)</title>
        <description>Number of subjects in whom IV antibiotics were utilized due to serious infection during the treatment phase</description>
        <time_frame>up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>IV Antibiotics (Individual Drugs Unspecified) Utilized Due to Serious Infection (Treatment Phase)</title>
          <description>Number of subjects in whom IV antibiotics were utilized due to serious infection during the treatment phase</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IV Antibiotics (Individual Drugs Unspecified) Utilized Due To Serious Infection (Annual Follow-Up Phase)</title>
        <description>Number of subjects in whom IV antibiotics were utilized due to serious infection during the annual follow-up phase</description>
        <time_frame>up to 5 years</time_frame>
        <population>participants with annual follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>IV Antibiotics (Individual Drugs Unspecified) Utilized Due To Serious Infection (Annual Follow-Up Phase)</title>
          <description>Number of subjects in whom IV antibiotics were utilized due to serious infection during the annual follow-up phase</description>
          <population>participants with annual follow up data</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe Neutropenia (Treatment Phase)</title>
        <description>Number of infections associated with severe neutropenia at onset during the treatment phase</description>
        <time_frame>up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Neutropenia (Treatment Phase)</title>
          <description>Number of infections associated with severe neutropenia at onset during the treatment phase</description>
          <units>number of infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Severe Neutropenia (Annual Follow-Up Phase)</title>
        <description>Number of infections associated with severe neutropenia at onset during the annual follow-up phase</description>
        <time_frame>up to 5 years</time_frame>
        <population>participants with annual follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Severe Neutropenia (Annual Follow-Up Phase)</title>
          <description>Number of infections associated with severe neutropenia at onset during the annual follow-up phase</description>
          <population>participants with annual follow up data</population>
          <units>number of infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Relapses (Treatment Phase)</title>
        <description>Number of clinical relapses reported during the treatment phase of the trial</description>
        <time_frame>up to 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relapses (Treatment Phase)</title>
          <description>Number of clinical relapses reported during the treatment phase of the trial</description>
          <units>number of relapses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Relapses (Annual Follow-Up Phase)</title>
        <description>Number of clinical relapses reported during the annual follow-up phase of the trial</description>
        <time_frame>up to 5 years</time_frame>
        <population>participants with annual follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Novantrone Therapy</title>
            <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relapses (Annual Follow-Up Phase)</title>
          <description>Number of clinical relapses reported during the annual follow-up phase of the trial</description>
          <population>participants with annual follow up data</population>
          <units>number of relapses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Symptomatic CHF, Left Ventricular Ejection Fraction - Prior to Each Dose • Serious Infections, IV Antibiotics, or Assoc w/ Severe Neutropenia-evaluated. Novantrone Admin - Per PI • SAE, Clinical Relapses</title>
        <description>Outcomes are presented separately above apart from adverse events which are presented in the adverse event section</description>
        <time_frame>up to 5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 5 years. Combined serious adverse events are displayed for both the Treatment Phase and Annual Follow-Up Phase</time_frame>
      <desc>Only serious adverse events were collected in this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Novantrone Therapy</title>
          <description>Novantrone, 12 mg/m2 intravenously once every 3 months, until a 140 mg/m2 cumulative dose was reached</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Ventricular Hypokinesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Shock Septic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Bronchitis Viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cellulitis Gangrenous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Fungal Skin Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Enterococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Wound Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ejection Fraction Decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Methicilin-resistant Staphylococcal Aureus Test Positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Spinal Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Acute Myeloid Leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Acute Promyelocytic Leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Chronic Myeloid Leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pituitary Tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Muscle Spasticity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Carotid Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Incomplete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pleuritic Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Drug Delivery Device Implantation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Medical Device Implantation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="509"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="509"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fernando Dangond, M.D., Medical Responsible</name_or_title>
      <organization>EMD Serono, Inc.</organization>
      <phone>+1 781 681 2348</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

